• Sanofi SA (NASDAQ: SNY) withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC) regarding the acquisition of Provention Bio Inc (NASDAQ: PRVB).

• Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion.

• The agency, it added, needed more time to look at the deal and “information recently provided to them,” Sanofi said in an SEC filing.

• In its disclosure, Sanofi added that “withdrawing and refiling premerger notifications is a standard procedure to provide additional time for antitrust review of certain transactions.”

• The move effectively reset the FTC’s 15-day preliminary review clock for a cash tender transaction, and the agency now has until the end of April 25 to decide.

• Hence, Sanofi is extending its offer to buy all of Provention’s shares by six days to the end of April 26.

• Following a deal announced on March 13, Sanofi filed its premerger report with the FTC on March 24.

• Despite the FTC hiccup, Sanofi said it still expects to close the deal in the second quarter of this year.

• Price Action: SNY shares are up 0.38% at $55.20 on the last check Tuesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.